It is suggested that TCT could reduce myocardial inflammation and myocardial fibrosis by inhibiting the activation of the NLRP3 inflammasome signaling pathway and improve the cardiac function of DCM rats, thus playing a role in the treatment of DCM. The gene discussed is NLRP3; the disease is familial dilated cardiomyopathy.